Skip to main content

Who Flares in Giant Cell Arteritis & Polymyalgia Rheumatica?

Dr. Janet Pope | Abstracts 1892 and 1893 | ACR 2026

Transcription

Hi, I'm Dr. Janet Pope. I'm reporting at RheumNow at ACR Orlando 2026. I wanted to talk about who flares in PMR and GCA. And there is another video you might want to watch on flaring of upadacitinib.

So abstract 1892, the SELECT-GCA RCT — to remind you, it's 15 milligrams of upadacitinib, or 7.5, or placebo. 7.5 didn't do all that well once the prednisone was rapidly tapered, so it isn't a dose that we're going to talk about. So if you were in full remission at 52 weeks on upadacitinib 15 milligrams a day, you're randomized in year two to stay on or go over to placebo. I think we all know that on placebo the flare rates are higher — of course they are. And what this found was that your ESR and CRP would still go up on upadacitinib if you flared. Flares were far less on upadacitinib than upadacitinib going over to placebo, but the ESR and CRP went up even higher if you were on placebo. And the amount of prednisone sparing was pretty darn good in the upadacitinib group versus placebo. So you probably need two years of treatment.

Now the other question is: what about in PMR — who flares, and what do we do about it, and how do we know what to do? So abstract 1893 was a subanalysis of secukinumab in PMR RCT, and it was presented looking at after you were in sustained remission at week 52, what happens when you stop secukinumab or you stop placebo, so to speak.

First of all, relapses are common. We know that in general in PMR you need more than a year of treatment. So in the secukinumab 300 milligram group, relapse is 44%; the same amount — it was 43% — on 150 milligrams; and on placebo it was about 20% higher, it was 61.5%. Also, if you looked at time to flare, placebo had a more rapid time to flare, and the higher dose of secukinumab had a delay of a couple of months further of being flare-free until you actually flared.

I think the bottom line is: if we're going to use an effective steroid-sparing drug in PMR, we now have secukinumab. Secukinumab will join the ranks. We have some data for sure on tocilizumab, but that's off label. If you're going to use a steroid-sparing drug, I think you really have to use it for two years in PMR as well.

Thanks. Follow me at Janet Berdope and follow us at RheumNow.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×